A possible anti-proliferative and anti-metastatic effect of irradiated riboflavin in solid tumours

Queiroz, Karla Cristiana de Souza; Zambuzzi, Willian Fernando; Souza, Ana Carolina Santos de; Silva, Rodrigo A. da; Machado, Daisy; Justo, Giselle Z.; Carvalho, Hernandes F.; Peppelenbosch, Maikel P.; Ferreira, Carmen Verı́ssima

doi:10.1016/j.canlet.2007.08.024

Cited by 54 publications

(72 citation statements)

References 30 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…During prolonged chemotherapy, the clinical usage of CP is restricted or discontinued because of its severe side effects like nephrotoxicity, hepatotoxicity, neurotoxicity and ototoxicity [2], [4], [19], [20]. Their amelioration has been a great challenge for medical research since its clinical implementation.…”

Section: Discussionmentioning

confidence: 99%

Riboflavin Ameliorates Cisplatin Induced Toxicities under Photoillumination

Hassan

Chibber²,

Khan³

et al. 2012

PLoS ONE

View full text Add to dashboard Cite

BackgroundCisplatin is an effective anticancer drug that elicits many side effects mainly due to induction of oxidative and nitrosative stresses during prolonged chemotherapy. The severity of these side effects consequently restricts its clinical use under long term treatment. Riboflavin is an essential vitamin used in various metabolic redox reactions in the form of flavin adenine dinucleotide and flavin mononucleotide. Besides, it has excellent photosensitizing property that can be used to ameliorate these toxicities in mice under photodynamic therapy.Methods and FindingsRiboflavin, cisplatin and their combinations were given to the separate groups of mice under photoilluminated condition under specific treatment regime. Their kidney and liver were excised for comet assay and histopathological studies. Furthermore, Fourier Transform Infrared Spectroscopy of riboflavin-cisplatin combination in vitro was also conducted to investigate any possible interaction between the two compounds. Their comet assay and histopathological examination revealed that riboflavin in combination with cisplatin was able to protect the tissues from cisplatin induced toxicities and damages. Moreover, Fourier Transform Infrared Spectroscopy analysis of the combination indicated a strong molecular interaction among their constituent groups that may be assigned for the protective effect of the combination in the treated animals.ConclusionInclusion of riboflavin diminishes cisplatin induced toxicities which may possibly make the cisplatin-riboflavin combination, an effective treatment strategy under chemoradiotherapy in pronouncing its antineoplastic activity and sensitivity towards the cancer cells as compared to cisplatin alone.

show abstract

Section: Discussionmentioning

confidence: 99%

Riboflavin Ameliorates Cisplatin Induced Toxicities under Photoillumination

Hassan

Chibber²,

Khan³

et al. 2012

PLoS ONE

View full text Add to dashboard Cite

show abstract

“…Embryos were collected and the protein amount was obtained using Lysis Cocktail (50 mM Tris [tris(hydroxymethyl)aminomethane]-HCl [pH 7.4], 1% Tween 20, 0.25% sodium deoxycholate, 150 mM NaCl, 1 mM EGTA (ethylene glycol tetraacetic acid), 1 mM O-Vanadate, 1 mM NaF, and protease inhibitors [1 lg/ml aprotinin, 10 lg/ml leupeptin, and 1 mM 4-(2-amino-ethyl)-benzolsulfonyl-fluorid-hydrochloride] for 2 h on ice, as used previously (de Souza Queiroz et al 2007;de Fátima et al 2008;Bispo de Jesus et al 2008). After clearing by centrifugation, the protein concentration was determined using Lowry method (Hartree 1972).…”

Section: Immunoblotting Assaymentioning

confidence: 99%

Immunohistochemical approach reveals involvement of inducible nitric oxide synthase in rat late development

et al. 2009

View full text Add to dashboard Cite

To better understand the role of nitric oxide (NO) in mammal development, specifically in the transition of the fetal stages at birth, we studied the timing of cell-specific expression of inducible NO synthase (iNOS) isoform during gestational periods of rats, mainly at the late stages of intra-uterine development. Before experimentation, the samples were collected (from 17th to 21st gestational days), fixed in 10% buffered formalin and embedded in paraffin for histological procedures. Hereafter, the sections (5 mum thickness) obtained from different embryos were immunostained by avidin-biotin-immunoperoxidase technique, by using antibody against iNOS isoform. The most of cell immunopositive was suggestive of granulocyte-like cells and those cells were resident close to the blood vessels in different organs, such as: lung, liver or bone marrow environment. Sometimes we noted immunopositive cells in the blood flow, as reported in the thymus. In agreement, iNOS expression, obtained by western blotting analysis, showed the same profile. Together, our data shows that iNOS expression increased gradually during the late stages of rat development (from E17 to E21) and it was executed by cells close to blood vessels. Thus, we can clearly to predict that this expression was finely modulated and it contributes for time-line dependent NO production during rat late development.

show abstract

“…A more recent epigenetic role for parthenolide in cancer has been shown, by specifically inhibiting DNA methyltransferase 1 (DNMT1) and histone deacetylase 1 (HDAC1) activities, leading to DNA hypomethylation in vitro and in vivo (Liu et al, 2009;Ghantous et al, 2010). Also, the ability of plant secondary metabolites, such as vitamins, isothiocyanates, quercetin, catechins, resveratrol, epigallocatechin-3-gallate (EGCG), genistein and curcumin, to prevent and/or inhibit tumor growth, either alone or in combination with other anticancer drugs and/or other phytochemicals has been documented (de Souza et al, 2005;de Souza et al, 2006;Hemalswarya & Doble, 2006;de Souza Queiroz et al, 2007;Newman & Cragg, 2007;de Fátima et al, 2008a;Bailly, 2009;Camargo et al, 2011). In this respect, all-trans-retinoic acid (vitamin A) is now widely used for the treatment of myeloid leukemia (Sanz & Lo-Coco, 2011) and vitamin D is in clinical trial for this disease (Trump et al, 2006).…”

Section: Plants As a Valuable Source Of Anticancer Drugsmentioning

confidence: 99%

“…In addition, activation of this cascade led to an inhibition of mitogen activated protein kinases cJun N-terminal kinase (JNK), extracellular signal-regulated kinase (ERK) kinase (MEK) and ERK and survival mediators [Protein kinase B (PKB/Akt) and inhibitor of apoptosis protein 1 (IAP1)], upregulation of pro-apoptotic Bax and downregulation of cell cycle progression regulators (de Souza et al, 2006). The potential of such vitamin-derived products in solid tumors was also demonstrated in androgen-independent human prostate cancer (PC3) cells (de Souza Queiroz et al, 2007). As reported earlier, riboflavin photoproducts are cytotoxic to these cells in a Fas-FasL-dependent manner.…”

Section: Plants As a Valuable Source Of Anticancer Drugsmentioning

confidence: 99%

“…As reported earlier, riboflavin photoproducts are cytotoxic to these cells in a Fas-FasL-dependent manner. Furthermore, irradiated riboflavin inhibited matrix-degrading proteases, caused downregulation of vascular endothelial growth factor (VEGF) and upregulation of tissue inhibitor of metalloproteinase 1 (TIMP1), suggesting antimetastatic potential (de Souza Queiroz et al, 2007). The anticancer properties of curcumin, a natural phytochemical obtained from dried root and rhizome of the spice turmeric (Curcuma longa), has long been studied, with few analogues showing promising results as future candidates for clinical development (de Fátima et al, 2008a;Ravindran et al, 2009;Agrawal & Mishra, 2010).…”

Section: Plants As a Valuable Source Of Anticancer Drugsmentioning

confidence: 99%

See 1 more Smart Citation